AC Immune SA
ACIU2.200USD
+0.080+3.77%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
220.90MCap. mercado
PérdidaP/E TTM
Más Datos de AC Immune SA Compañía
AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
Información de la empresa
Símbolo de cotizaciónACIU
Nombre de la empresaAC Immune SA
Fecha de salida a bolsaSep 23, 2016
Director ejecutivoProf. Dr. Andrea Pfeifer, Ph.D.
Número de empleados133
Tipo de seguridadOrdinary Share
Fin del año fiscalSep 23
DirecciónEPFL Innovation Park
CiudadLAUSANNE
Bolsa de valoresNASDAQ Global Market Consolidated
PaísSwitzerland
Código postal1015
Teléfono41213459121
Sitio Webhttps://www.acimmune.com/
Símbolo de cotizaciónACIU
Fecha de salida a bolsaSep 23, 2016
Director ejecutivoProf. Dr. Andrea Pfeifer, Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Werner Lanthaler, Ph.D.
Dr. Werner Lanthaler, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
140.00K
+13.65%
Dr. Douglas E. (Doug) Williams, Ph.D.
Dr. Douglas E. (Doug) Williams, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
58.01K
+49.01%
Mr. Piergiorgio Donati
Mr. Piergiorgio Donati
Chief Technical Operations Officer
Chief Technical Operations Officer
45.80K
+86.78%
Mr. Howard Donovan
Mr. Howard Donovan
Chief Human Resources Officer
Chief Human Resources Officer
40.80K
+102.61%
Mr. Christopher Roberts
Mr. Christopher Roberts
Chief Financial Officer
Chief Financial Officer
38.05K
+201.94%
Prof. Carl June, M.D.
Prof. Carl June, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
25.97K
+183.81%
Dr. Anke Post, M.D., Ph.D.
Dr. Anke Post, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
9.80K
--
Dr. Monica Shaw, M.D.
Dr. Monica Shaw, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Roy E. Twyman, M.D.
Dr. Roy E. Twyman, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Prof. Dr. Monika Buetler, Ph.D.
Prof. Dr. Monika Buetler, Ph.D.
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Werner Lanthaler, Ph.D.
Dr. Werner Lanthaler, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
140.00K
+13.65%
Dr. Douglas E. (Doug) Williams, Ph.D.
Dr. Douglas E. (Doug) Williams, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
58.01K
+49.01%
Mr. Piergiorgio Donati
Mr. Piergiorgio Donati
Chief Technical Operations Officer
Chief Technical Operations Officer
45.80K
+86.78%
Mr. Howard Donovan
Mr. Howard Donovan
Chief Human Resources Officer
Chief Human Resources Officer
40.80K
+102.61%
Mr. Christopher Roberts
Mr. Christopher Roberts
Chief Financial Officer
Chief Financial Officer
38.05K
+201.94%
Prof. Carl June, M.D.
Prof. Carl June, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
25.97K
+183.81%
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: mar., 22 de jul
Actualizado: mar., 22 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
BVF Partners L.P.
19.74%
DH Capital GmbH & Co. KG
16.25%
Varuma AG
11.95%
Affiris AG
6.40%
Pfeifer (Andrea M. A Ph.D.)
2.94%
Other
42.71%
Accionistas
Accionistas
Proporción
BVF Partners L.P.
19.74%
DH Capital GmbH & Co. KG
16.25%
Varuma AG
11.95%
Affiris AG
6.40%
Pfeifer (Andrea M. A Ph.D.)
2.94%
Other
42.71%
Tipos de accionistas
Accionistas
Proporción
Corporation
34.60%
Hedge Fund
21.05%
Individual Investor
3.40%
Investment Advisor/Hedge Fund
2.09%
Investment Advisor
1.20%
Research Firm
1.02%
Bank and Trust
0.03%
Other
36.62%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
116
63.65M
63.39%
-3.52M
2025Q1
122
64.71M
64.45%
-3.00M
2024Q4
118
65.41M
66.11%
-3.57M
2024Q3
115
69.90M
70.65%
+1.39M
2024Q2
111
70.29M
70.97%
+1.59M
2024Q1
107
70.85M
71.52%
-2.28M
2023Q4
109
71.51M
72.19%
+11.62M
2023Q3
121
61.07M
72.18%
-889.36K
2023Q2
131
61.41M
72.77%
+1.91M
2023Q1
140
59.93M
71.03%
-2.26M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
BVF Partners L.P.
19.82M
19.74%
+300.00K
+1.54%
Mar 31, 2025
DH Capital GmbH & Co. KG
16.32M
16.25%
--
--
Dec 31, 2024
Varuma AG
12.00M
11.95%
--
--
Dec 31, 2024
Affiris AG
6.43M
6.4%
-150.00K
-2.28%
May 31, 2024
Pfeifer (Andrea M. A Ph.D.)
2.96M
2.94%
+534.84K
+22.09%
Dec 31, 2024
Wells Fargo Advisors
997.62K
0.99%
+1.99K
+0.20%
Mar 31, 2025
Renaissance Technologies LLC
803.47K
0.8%
+63.27K
+8.55%
Mar 31, 2025
BlackRock Financial Management, Inc.
642.79K
0.64%
-920.44K
-58.88%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
393.51K
0.39%
-31.72K
-7.46%
Mar 31, 2025
Northern Trust Global Investments Limited
377.09K
0.38%
-25.95K
-6.44%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
ProShares Ultra Nasdaq Biotechnology
0.02%
Invesco Nasdaq Biotechnology ETF
0.02%
iShares Biotechnology ETF
0.01%
DFA Dimensional US Sustainability Core 1 ETF
0%
iShares Health Innovation Active ETF
0%
ALPS Medical Breakthroughs ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
ProShares Ultra Nasdaq Biotechnology
Proporción0.02%
Invesco Nasdaq Biotechnology ETF
Proporción0.02%
iShares Biotechnology ETF
Proporción0.01%
DFA Dimensional US Sustainability Core 1 ETF
Proporción0%
iShares Health Innovation Active ETF
Proporción0%
ALPS Medical Breakthroughs ETF
Proporción0%
Invesco NASDAQ Future Gen 200 ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
